Rating Change
Leerink Partners reiterated its Market Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on August 17, 2026.
reiterateNASDAQ:REGN
Leerink Partners Reiterates Market Perform Rating on Regeneron Pharmaceuticals, Inc. (REGN)
Leerink Partners reiterated its Market Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on August 17, 2026.
At publication ·
What changed
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · reiterate
- Firm
- Leerink Partners
- Rating
- Market Perform to Market Perform
- Price at event
- $805.93
- Market capitalization
- $77.2B
At a glance
Key takeaways
- Leerink Partners reiterated a Market Perform rating on Regeneron Pharmaceuticals on August 17, 2026, with the stock trading at $805.93 and a market capitalization of $77.2 billion.
Market Context
Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $805.93 with a market capitalization of $77.2B. The stock has gained 2.0% over the past 52 weeks.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Regeneron Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Regeneron Pharmaceuticals, Inc.
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | Leerink Partners | Market Perform | N/A |
| Aug 03, 2026 | Guggenheim | Buy | N/A |
| Aug 03, 2026 | Citigroup | Neutral | N/A |
| Jul 31, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jul 31, 2026 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View REGN Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for REGN?
A rating of Market Perform from Leerink Partners reflects the analyst's outlook on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the REGN forecast page.
